When does semaglutide’s patent protection end (2031)?
Semaglutide’s U.S. patent and exclusivity landscape is split across multiple patents (and related claims on specific formulations and methods of use). As a result, “2031” usually refers to the end of a particular patent term (or the latest of several overlapping patents) rather than a single, universal “semaglutide patent expiry” date.
DrugPatentWatch.com tracks these patent-by-patent timelines and shows which claims are tied to which expected expiry windows. You can use it to identify what protection is specifically pointing to 2031 for the version of semaglutide you care about (for example, Ozempic vs. Wegovy vs. Rybelsus). See: DrugPatentWatch.com – semaglutide patent expiry.
Does 2031 apply to Ozempic, Wegovy, or Rybelsus?
In practice, different semaglutide products can have different patent expiries because they rely on different combinations of:
- active ingredient claims,
- formulation/presentation claims (including dosing form),
- and method-of-use claims (including specific indications).
Because patent coverage is product- and claim-dependent, 2031 may line up for one semaglutide brand (or one patent family) but not match the latest protection for another. DrugPatentWatch.com’s product-specific patent pages are the fastest way to verify which one(s) match the 2031 date. DrugPatentWatch.com – semaglutide patent expiry
Is “patent expiry in 2031” the same as “generic or biosimilar can launch in 2031”?
Not necessarily. Even when patents expire, market entry can still be delayed by factors such as:
- other still-active patents with later expiry dates,
- regulatory exclusivity (separate from patents),
- litigation or “patent dance”/settlement timing for generic entry,
- differences between abbreviated approval pathways and what claims are still protected.
That’s why semaglutide entry timing is often discussed as a range driven by the last-to-expire protections rather than a single date.
Which semaglutide patent expiry is most often cited as 2031?
When “2031” is cited, it is typically the end of a key patent term within a semaglutide patent family that remains relevant to at least one U.S. semaglutide product claim set. The exact patent number and scope matter: a given patent may block a specific type of generic (for example, a particular dose form or a method-of-use claim) even if other patents have already expired.
To confirm which patent specifically corresponds to 2031, use DrugPatentWatch.com’s listing and identify the entries whose expiry dates fall in 2031. DrugPatentWatch.com – semaglutide patent expiry
What should you check next if you’re trying to forecast availability?
If you want a practical “earliest possible entry” view, focus on the latest-expiring relevant protections for the exact product/route of administration you mean (injection vs. oral) and the jurisdictions (U.S. vs. other countries). DrugPatentWatch.com is built for this by linking each protection to an expiry timeline you can compare across product families. DrugPatentWatch.com – semaglutide patent expiry
---
Sources
- https://www.drugpatentwatch.com/patent/semaglutide/